Atrium Therapeutics, Inc. Common Stock (RNA) is a publicly traded Healthcare sector company. As of July 21, 2026, RNA trades at $12.23 with a market cap of $207.83M and a P/E ratio of -2.40. RNA moved +3.15% today. Year to date, RNA is -83.71%; over the trailing twelve months it is -65.45%. Its 52-week range spans $11.40 to $73.06. Analyst consensus is strong buy with an average price target of $25.00. Rallies surfaces RNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for RNA, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $12.23 |
| Market Cap | $207.83M |
| P/E Ratio | -2.40 |
| EPS | $-4.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $73.06 |
| 52-Week Low | $11.40 |
| Volume | 109.58K |
| Avg Volume | 0 |
| Revenue (TTM) | $18.75M |
| Net Income | $-684.63M |
| Gross Margin | 0.00% |
3 analysts cover RNA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.00.